Liraglutide in Parkinson's Disease

Condition: Parkinson's disease

Eligibility

Key Inclusion Criteria

  • Diagnosis of idiopathic Parkinson's disease
  • Between 25 and 85 years old
  • Responsive to levodopa or dopaminergic treatment

Key Exclusion Criteria

  • Diagnosis or suspicion of other causes for Parkinsonism
  • Active treatment with anticholinergic medications
  • Known abnormality on brain imaging considered to cause symptoms or signs of neurological dysfunction

Full Study Name

A Phase II, Randomized, Double-Blinded, Placebo-Controlled Trial of Liraglutide in Parkinson's Disease (IRB no. 44598)

Summary

The purpose of this study is to examine the safety and efficacy of an insulin resistance treatment drug, liraglutide, in patients with Parkinson’s disease (PD). Patients with PD commonly show glucose intolerance and may benefit from medications originally designed to treat insulin resistance. Researchers aim to determine whether liraglutide can potentially slow down or stop the progression of Parkinson’s disease. The study will compare the effects of liraglutide to placebo (inactive substance). The use of liraglutide in this study is investigational.


Principal Investigator

Michele Tagliati, MD